|
[1]
|
Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Wang, H., Xuan, T.T., Chen, Y., et al. (2020) Investigative Therapy for Advanced Esophageal Cancer Using the Option for Combined Immunotherapy and Chemotherapy. Immunotherapy, 12, 697-703. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Zhong, M.X., Xue, J.M., Zeng, X.Z., et al. (2021) PD-1/PD-L1 In-hibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Ran-domized Controlled Trials. Journal of Oncology, 2021, Article ID: 3048974. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., et al. (2006) Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991-4997. [Google Scholar] [CrossRef]
|
|
[5]
|
Al-Batran, S.E., Hartmann, J.T., Probst, S., et al. (2008) Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 26, 1435-1442. [Google Scholar] [CrossRef]
|
|
[6]
|
Kelly, R.J. (2019) The Emerging role of Immunotherapy for Esophageal Cancer. Current Opinion in Gastroenterology, 35, 337-343. [Google Scholar] [CrossRef]
|
|
[7]
|
Irelli, A., Sirufo, M.M., D’ugo, C., et al. (2020) Sex and Gender Influences on Cancer Immunotherapy Response. Biomedicines, 8, Article No. 232. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Lee, J.B., Ha, S.J. and Kim, H.R. (2021) Clinical Insights into Novel Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 12, Article ID: 681320. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Chang, X., Lu, X., Guo, J., et al. (2019) Interventional Therapy Combined with Immune Checkpoint Inhibitors: Emerging Opportunities for Cancer Treatment in the Era of Immunother-apy. Cancer Treatment Reviews, 74, 49-60. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Jiao, R., Luo, H., Xu, W., et al. (2019) Immune Checkpoint Inhib-itors in Esophageal Squamous Cell Carcinoma: Progress and Opportunities. OncoTargets and Therapy, 12, 6023-6032. [Google Scholar] [CrossRef]
|
|
[11]
|
Kim, H.D. and Park, S.H. (2019) Immunological and Clinical Implica-tions of Immune Checkpoint Blockade in Human Cancer. Archives of Pharmacal Research, 42, 567-581. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Da Silva, L.L., Aguiar Jr., P.N., Park, R., et al. (2021) Compar-ative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Sys-tematic Review and Network Meta-Analysis of Phase III Clinical Trials. Cancers, 13, Article No. 2614. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Fukuoka, E., Yamashita, K., Tanaka, T., et al. (2019) Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-Infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma. Anticancer Research, 39, 4539-4548. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Pfirschke, C., Engblom, C., Rickelt, S., et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 44, 343-354. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Sakai, H., Takeda, M., Sakai, K., et al. (2019) Impact of Cyto-toxic Chemotherapy on PD-L1 Expression in Patients with Non-Small Cell Lung Cancer Negative for EGFR Mutation and ALK Fusion. Lung Cancer, 127, 59-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Shitara, K., Van Cutsem, E., Bang, Y.J., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Ajani, J.A., D’amico, T.A., Bentrem, D.J., et al. (2019) Esoph-ageal and Esophagogastric Junction Cancers, Version 2. 2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 855-883. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kitagawa, Y., Uno, T., Oyama, T., et al. (2019) Esophageal Cancer Practice Guidelines 2017 Edited by the Japan Esophageal Society: Part 1. Esophagus, 16, 1-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wang, F., Qi, Y., Meng, X., et al. (2021) Camrelizumab in Com-bination with Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Open-Label, Phase II Study. Journal of Clinical Oncology, 39, e16072. [Google Scholar] [CrossRef]
|
|
[20]
|
Yan, X., Zhao, J., Lei, J., et al. (2021) 144P Tisleli-zumab Combined with Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Cancer (TD-NICE): A Single Arm, Phase II Study. Annals of Oncology, 32, S1442. [Google Scholar] [CrossRef]
|
|
[21]
|
黄毅雄, 林义进, 朱坤寿. 食管鳞癌术前辅助治疗中替雷利珠单抗联合白蛋白紫杉醇+奈达铂与单纯化疗疗效的对比分析[J]. 福建医学杂志, 2021, 43(6): 116-119.
|
|
[22]
|
Kelly, R.J., Ajani, J.A., Kuzdzal, J., et al. (2021) Adjuvant Nivolumab in Resected Esophageal or Gas-troesophageal Junction Cancer. The New England Journal of Medicine, 384, 1191-1203. [Google Scholar] [CrossRef]
|
|
[23]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab Plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40. [Google Scholar] [CrossRef]
|
|
[24]
|
André, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembroli-zumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. [Google Scholar] [CrossRef]
|
|
[25]
|
Jin, Z., Shen, J., Wang, C., et al. (2021) Narrative Re-view of Pembrolizumab for the Treatment of Esophageal Cancer: Evidence and Outlook. Annals of Translational Medi-cine, 9, 1189. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pem-brolizumab Plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. [Google Scholar] [CrossRef]
|
|
[27]
|
Luo, H., Lu, J., Bai, Y., et al. (2021) Effect of Camreli-zumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. Journal of the American Medical Association, 326, 916-925. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
张溪夏. PD-1/PD-L1单抗在复发转移性鼻咽癌中的研究进展[J]. 中国肿瘤临床, 2020, 47(23): 1231-1235.
|
|
[29]
|
Kato, K., Cho, B.C., Takahashi, M., et al. (2019) Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 1506-1517. [Google Scholar] [CrossRef]
|
|
[30]
|
Vivaldi, C., Catanese, S., Massa, V., et al. (2020) Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist? International Journal of Molecular Sciences, 21, Article No. 1658. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Shen, L., Kato, K., Kim, S.B., et al. (2021) RATIONALE 302: Ran-domized, Phase 3 Study of Tislelizumab versus Chemotherapy as Second-Line Treatment for Advanced Unresec-table/Metastatic Esophageal Squamous Cell Carcinoma. Journal of Clinical Oncology, 39, 4012. [Google Scholar] [CrossRef]
|
|
[32]
|
Huang, J., Xu, J., Chen, Y., et al. (2020) Camrelizumab versus Investigator’s Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squa-mous Cell Carcinoma (ESCORT): A Multicentre, Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 21, 832-842. [Google Scholar] [CrossRef]
|
|
[33]
|
Shah, M.A., Kojima, T., Hochhauser, D., et al. (2019) Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients with Advanced, Metastatic Adenocarcino-ma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncology, 5, 546-550. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Harada, K., Rogers, J.E., Iwatsuki, M., et al. (2020) Recent Advances in Treating Oesophageal Cancer. F1000Research, 9, 1189. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Song, H., Liu, X., Jiang, L., et al. (2021) Current Status and Prospects of Camrelizumab, a Humanized Antibody against Programmed Cell Death Receptor 1. Recent Patents on An-ti-Cancer Drug Discovery, 16, 312-332. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Toki, M.I., Syrigos, N. and Syrigos, K. (2021) Hy-perprogressive Disease: A Distinct Pattern of Progression to Immune Checkpoint Inhibitors. International Journal of Cancer, 149, 277-286. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Moser, J.C. and Hu-Lieskovan, S. (2020) Mecha-nisms of Resistance to PD-1 Checkpoint Blockade. Drugs, 80, 459-465. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Galluzzi, L., Humeau, J., Buque, A., et al. (2020) Immunostim-ulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors. Nature Reviews Clinical Oncology, 17, 725-741. [Google Scholar] [CrossRef] [PubMed]
|